HanchorBio
Business Services · Taiwan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1號 Neihu District Section 1 Tiding Blvd ...Phone Number
+886 227921366Website
www.hanchorbio.comRevenue
<$5 MillionIndustry
About HanchorBio
HanchorBio Org Chart
Is HanchorBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at HanchorBio
Check if HanchorBio has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on HanchorBio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if HanchorBio had a recent Job posting/layoffs
HanchorBio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when HanchorBio launches new products
Funding: Get notified immidiatlly once HanchorBio has new funding data
Website visits: Recent activity has been detected on your website
Check out if HanchorBio is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined HanchorBio as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
HanchorBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
HanchorBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about HanchorBio.
HanchorBio Tech Stack
A closer look at the technologies used by HanchorBio
HanchorBio News & Media
HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology
Collaboration connects internationally recognized cancer multi-omics research with HanchorBio's clinical-stage immuno-oncology platform to accelerate biomarker-driven drug development and strengthen next-generation precision immunotherapy TAIPEI and SHANGHAI and SAN FRANCISCO, Aug. 9,...HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to broaden the development path for HCB101, its lead oncology asset, through a new partnership with InxMed. The Taiwan-listed clinical-stage biotech announced that its subsidiary, FBD Biologics Limited, has signed a sHanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to...HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions
Global clinical-stage biotech x FBDB™ platform and multi-indication development strategy for lead program HCB101 TAIPEI, SHANGHAI, SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation...
Top Business Services Companies
Frequently Asked Questions Regarding HanchorBio
HanchorBio is a global clinical-stage biotechnology company focused on pioneering transformative immunotherapies for oncology and autoimmune diseases. The company is dedicated to innovating for life and inspiring hope through its advanced research and development projects, which include over 100 patent applications and a significant investment in R... Read More